Vertex Pharmaceuticals (VRTX) Akcija Цена
Vertex Pharmaceuticals Цена
U poslednjih 19 godina prihod Vertex Pharmaceuticals rastao je 23,6 % godišnje i dostigao 12,07 Млрд USD. Zarada po akciji rasla je 40,3 % godišnje u poslednjih 14 godina. Za Vertex Pharmaceuticals neto marža od 32,7 % je porasla u odnosu na 30,9 % pre nekoliko godina. Konsenzusna 12-mesečna ciljana cena za Vertex Pharmaceuticals je 608,00 USD, oko iznad kurs za 18,1 %. Od 39 analitičara 32 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Vertex Pharmaceuticals
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Vertex Pharmaceuticals poslovni model i analiza akcije
Često postavljana pitanja o akciji Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 579,29 USD za akciju Vertex Pharmaceuticals (medijana: 608,00 USD), što znači +11,3 % u odnosu na poslednju cenu. Konsenzus se zasniva na 39 ocena.
39 analitičara trenutno ocenjuje akciju Vertex Pharmaceuticals: 32 preporučuje kupovinu, 6 držanje i 1 prodaju. Za 2026 analitičari očekuju da Vertex Pharmaceuticals ostvari prihod 13,26 Млрд USD i zaradu po akciji 17,99 USD.
Po trenutnom kursu akcija Vertex Pharmaceuticals kotira 469,05 EUR (515,02 USD).
Akcija Vertex Pharmaceuticals (VRTX) kotira na 11 berze, uključujući: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
očekivana prihod od Vertex Pharmaceuticals je 13,26 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Vertex Pharmaceuticals je 4,61 Млрд USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Vertex Pharmaceuticals je trenutno 28,63. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Vertex Pharmaceuticals.
Odnos cene i prihoda (KUV) za Vertex Pharmaceuticals je trenutno 9,95. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Vertex Pharmaceuticals.
Eulpool score kvaliteta za Vertex Pharmaceuticals je 6/10.
ISIN za Vertex Pharmaceuticals je US92532F1003. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Vertex Pharmaceuticals je 882807. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Vertex Pharmaceuticals je VRTX. Simbol tikera se koristi za trgovinu akcijama Vertex Pharmaceuticals na berzanskom tržištu.
Vertex Pharmaceuticals акција
Vertex Pharmaceuticals Peer grupa
Vertex Pharmaceuticals Тикер
Vertex Pharmaceuticals FIGI
Sve ključne metrke i detaljne analize Vertex Pharmaceuticals u dubinskoj analizi
Naša analiza akcija za akciju Vertex Pharmaceuticals uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Vertex Pharmaceuticals. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize:





